Photodynamic therapy treatment of oral cavity cancer in patients with comorbidities

We report the experience of radical treatment by photodynamic therapy of patients with squamous cell carcinoma of oral cavity with serious side diseases. Completed treatment of two patients with serious side diseases (HIV infection with associated pulmonary hypertension of high degree and cardiac pathology) suffered from cancer of oral cavity. Extensive surgical treatment and/or aggressive course of chemoradiation therapy were not indicated to them due to concomitant pathology. Both patients were diagnosed with squamous cell carcinoma of oral cavity, with appropriate stage Ist. сT1N0M0. Patients received treatment by photodynamic therapy with chorine photosensitizer in dose 1 mg/kg. Options of photodynamic were: output power – 1.5W, power density – 0.31 W/cm², light dose – 300 J/cm². After one time session of photodynamic therapy, in both cases full response was diagnosed (according to RECIST 1.1). In one case the second session of photodynamic therapy was performed due to concomitant disease of oral cavity – multiply lesions of leukoplakia and after was diagnosed full remission of all lesions. Major adverse event was pain during the first 5-7 days after treatment, curable by painkillers. Follow-up (IQR) was 12 and 18 month respectively with no evidence of progression. It is available to avoid extensive surgical treatment and aggressive course of chemoradiation therapy (as an alternative) with the use of photodynamic therapy. Photodynamic therapy is minimally invasive method of radical treatment of localized squamous cell carcinoma of oral cavity with minimal adverse events, and could be especially relevant in patients with serious concomitant diseases.

1. NCCN Clinical Practice Guidelines in Oncology, Cancer of the Oral Cavity, 2022, Version 2.

2. Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefèbvre J.L., Greiner R.H., Giralt J. et al. European Organization for Research and Treatment of Cancer Trial 22931 Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer, N Engl J Med, 2004, vol. 350(19), pp. 1945-1952. doi: 10.1056/NEJMoa032641. PMID: 15128894.

3. Cooper J.S., Zhang Q., Pajak T.F., Forastiere A.A., Jacobs J., Saxman S.B. et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck, Int J Radiat Oncol Biol Phys, 2012, vol. 84(5), рр. 1198-1205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30 PMID: 22749632; PMCID: PMC3465463.

4. Bachaud J.M., Cohen-Jonathan E., Alzieu C., David J.M., Serrano E., Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: nal report of a randomized trial, Int J Radiat Oncol Biol Phys, 1996, vol. 36(5), рр. 999-1004. doi: 10.1016/s0360-3016(96)00430-0. PMID: 8985019.

5. Wu Q., Mohan R., Morris M. et al. Simultaneous integrated boost intensitymodulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results, Int J Radiat Oncol Biol Phys, 2003, vol. 56, рр. 573-585.

6. Panaseikin Yu.A., Sevryukov F.E., Isaev P.A., Vasilkov S.V., Derbugov D.N., Semin D.Yu., Medvedev V.S., Polkin V.V., Kaprin A.D., Ivanov S.A. Method of treatment of the initial stages of oral cancer, 2003, Patent No. 2713940 11.02.2020 Byul.5.

7. Mazeron J.J., Ardiet J.M., Haie-Meder C. et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas, Radiother Oncol, 2009, vol. 91(2). рр. 150-156.

8. Ye W., Schmitt N.C. Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients? Annals of Translational Medicine, 2019, vol. 7(S1). – P. 14.

9. Chow L.Q., Haddad R., Gupta S. et al. Antitumor activity of pembrolizumab in biomarker– unselected patients with recurrent and or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort, J Clin Oncol, 2016, vol. 34, рр. 3838-3845.

10. Hsu C., Lee S.H., Ejadi S. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study, J Clin Oncol, 2017, vol. 35, рр. 4050-4056.

11. Lebedev M.V., Abdullina Yu.A., Zakharova I.Yu. Specialized medical care for patients with malignant neoplasms of the maxillofacial area in the Penza region of Russia, Biomedical Photonics, 2021, vol. 10(3), рр. 23-31. https://doi.org/10.24931/2413-9432-2021-10-3-23-31.

12. Ibarra A.M.C., Cecatto R.B., Motta L.J., Dos Santos Franco A.L. et al. Photodynamic therapy for squamous cell carcinoma of the head and neck: narrative review focusing on photosensitizers, Lasers Med Sci, 2022, vol. 37(3), рр. 1441-1470. doi: 10.1007/s10103-021-03462-3 Epub 2021 Dec 2 PMID: 34855034.

13. Filonenko E.V. The history of development of fluorescence diagnosis and photodynamic therapy and their capabilities in oncology, Russian Journal of General Chemistry, 2015, vol. 85(1), рр. 211-216. doi: 10.1134/S1070363215010399.

14. Lebedev M.V., Kerimova K.I. Optimization of provision of specialized medical care for patients with maxillofacial neoplasms in the Penza region of Russia, Biomedical Photonics, 2021, vol. 10(1), рр. 32-38. doi: 10.24931/2413-9432-2021-10-1-32-38.

15. Huang Z. A. Review of Progress in Clinical Photodynamic Therapy, Technol. Cancer Res. Treat, 2005, vol. 4(3), рр. 283-293.

16. D’Cruz A., Wenig B., Iqbal A. et al.: Foscan-mediated photodynamic therapy in the palliative treatment of advanced head and neck cancer, Poster presentation Fifth International Congress on Head and Neck Oncology; San Francisco, USA, 2000.

17. Panaseykin Y.A., Filonenko E.V., Sevrukov F.E., Kapinus V.N., Polkin V.V., Isaev P.A., Kaprin A.D., Ivanov S.A. Possibilities of photodynamic therapy in the treatment of malignant tumors of the oral cavity, Biomedical Photonics, 2021, vol. 10(3), рр. 32-38.